Summary of Key Points Core Viewpoint - The company has been actively repurchasing its shares, indicating a strategy to support its stock price amidst a decline in market performance [1][2]. Share Buyback Activity - On October 14, the company repurchased 183,300 shares at a price range of HKD 29.620 to HKD 31.140, totaling HKD 5.495 million [1]. - The stock closed at HKD 29.680 on the same day, reflecting a decrease of 4.63% with a total trading volume of HKD 70.765 million [1]. - Since September 10, the company has conducted share buybacks for 23 consecutive days, acquiring a total of 3.6138 million shares for a cumulative amount of HKD 115 million, during which the stock price has dropped by 10.84% [1]. Year-to-Date Buyback Summary - Year-to-date, the company has executed 46 buyback transactions, acquiring a total of 6.5684 million shares for a total expenditure of HKD 209 million [2]. - Detailed buyback data shows fluctuations in share prices and amounts spent on repurchases, with the highest buyback price recorded at HKD 37.700 and the lowest at HKD 28.100 [3].

Core Viewpoint - The company, Guoshengtang (02273.HK), announced a share buyback on October 14, 2023, spending HKD 5.495 million to repurchase 183,000 shares [1] Summary by Category Company Actions - Guoshengtang executed a buyback of 183,000 shares at a total cost of HKD 5.495 million on October 14, 2023 [1]

固生堂(02273)发布公告，该公司于2025年10月14日斥资549.5万港元回购18.33万股股份，每股回购价格 为29.62-31.14港元。 ...

Core Viewpoint - The company, Gushengtang (02273), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - Gushengtang plans to repurchase 183,300 shares at a total cost of HKD 5.495 million [1] - The buyback price per share ranges from HKD 29.62 to HKD 31.14 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年10月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 1). | 購回股份 (擬註銷但尚未註銷) | | 100,000 | 0.0424 % | HKD | 33.5652 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年9月1日 | | | | | | 2). | 購回股份（擬註銷但尚未註銷） | | 140,900 | 0.0597 % | HKD | 33.0529 | | | 變動日期 | 2025年9月2日 | | | | | | 3). | 購回股份（擬註銷但尚未註銷） | | 51,400 | ...

智通财经APP讯，固生堂(02273)发布公告，于2025年10月13日，该公司斥资285.83万港元回购9.23万股 股份，每股回购价格为30.7-31.16港元。 ...

Core Viewpoint - The company, Guoshengtang (02273), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 92,300 shares at a total cost of HKD 2.8583 million [1] - The buyback price per share ranges from HKD 30.7 to HKD 31.16 [1] - The buyback is scheduled for October 13, 2025 [1]

Group 1 - The company, Guoshengtang (02273.HK), announced a share buyback on October 13, 2025, costing HKD 2.858 million to repurchase 92,000 shares [1] - The buyback price ranged from HKD 30.7 to HKD 31.16 per share [1]

表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年10月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 ( ...

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector's potential for a reversal in 2025, particularly focusing on innovative drugs and the recovery of left-side sectors as the biggest investment opportunities for the year [5][14]. Core Insights - The innovative drug sector is expected to continue its upward trend, with BD (business development) activities anticipated to catalyze market movements. The upcoming ESMO conference (October 17-21) is highlighted as a key event for clinical data disclosures from domestic innovative drug companies [2][13]. - The report emphasizes the importance of recent Nobel Prize discoveries related to peripheral immune tolerance, which are relevant to the development of new therapies in oncology and autoimmune diseases. This underscores the significance of innovation in these fields [40][50]. - The report notes that the CXO industry in China is entering a recovery phase, with improvements expected in industry orders, capacity utilization, and performance metrics due to enhanced domestic investment and financing data [2][5]. Summary by Sections Innovative Drugs - The innovative drug sector has seen a recent pullback, but the long-term upward trend remains intact. The report suggests that the market is awaiting further BD catalysts and highlights the importance of upcoming clinical data from the ESMO conference [2][13]. - The report indicates that the overall sentiment in the innovative drug sector is still positive, with a focus on potential breakthroughs in cancer and autoimmune therapies following the recent Nobel Prize discoveries [40][50]. Biologics - Novo Nordisk announced an agreement to acquire Akero for $4.7 billion, with Akero's FGF21 analog EFX showing promise as a leading therapy for metabolic dysfunction-related fatty liver disease (MASH) [3][51]. - The report suggests that EFX is the only drug in Phase 2 trials demonstrating significant fibrosis regression in F4 patients, highlighting the need for continued attention to developments in this area [51][57]. Medical Devices - The commercialization of innovative products is accelerating, with domestic replacements making significant progress. For instance, MicroPort's Tumi laparoscopic surgical robot has surpassed 100 global orders and is leading the domestic market share [4][58]. - The report notes that the Tumi robot has received market access in over 60 countries and regions, with a strong presence in high-end markets such as Europe [60][62]. Traditional Chinese Medicine - There has been a continuous increase in new drug IND and NDA applications for traditional Chinese medicine, with 92 new IND applications and 42 NDA applications reported in the first nine months of 2025 [3][64]. - The report highlights ongoing policy support for traditional Chinese medicine, which is expected to drive further innovation and development in this sector [64][65].